A 2025 JAMA Network Open study analyzing two years of paid search results found that 11% of the search keywords or phrases paid for by Novo Nordisk contained the word "weight", even though the drug Ozempic is approved for type 2 diabetes and not for weight loss.
November 04, 2025
high
statistical
Analysis of paid search (sponsored) results purchased by a pharmaceutical manufacturer.
A 2025 Phase 2 clinical trial funded by Eli Lilly that enrolled 263 adults who were overweight or obese without diabetes found that once-weekly injectable eloralintide produced dose-dependent weight loss of 9.5% to 20.1% of body weight after 48 weeks, compared with a 0.4% mean weight change in the placebo group.
January 01, 2025
high
temporal
Primary efficacy results from a Phase 2 trial of eloralintide
A 2025 Phase 2 clinical trial of eloralintide reported that treatment was associated with improvements in waist circumference, blood pressure, lipid profiles, glycemic control, and markers of inflammation in adults who were overweight or obese without diabetes.
January 01, 2025
high
temporal
Cardiometabolic and inflammatory secondary outcomes reported in the Phase 2 trial
A 2025 Phase 2 trial of eloralintide (manufactured by Eli Lilly) in 263 adults with overweight or obesity but without diabetes found that after 48 weeks participants lost between 9.5% and 20.1% of body weight versus 0.4% for placebo, and the treatment was associated with improvements in waist circumference, blood pressure, lipid profiles, glycemic control, and markers of inflammation, with up to 90% of participants improving by at least one BMI category.
January 01, 2025
high
temporal
Results and key outcomes from a 2025 Phase 2 clinical trial of the investigational drug eloralintide.